CA2532203A1 - Methodes de diagnostic et de traitement de l'asthme et d'autres maladies respiratoires reposant sur une association d'haplotypes - Google Patents

Methodes de diagnostic et de traitement de l'asthme et d'autres maladies respiratoires reposant sur une association d'haplotypes Download PDF

Info

Publication number
CA2532203A1
CA2532203A1 CA002532203A CA2532203A CA2532203A1 CA 2532203 A1 CA2532203 A1 CA 2532203A1 CA 002532203 A CA002532203 A CA 002532203A CA 2532203 A CA2532203 A CA 2532203A CA 2532203 A1 CA2532203 A1 CA 2532203A1
Authority
CA
Canada
Prior art keywords
mlk1
inhibitor
nucleic acid
individual
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002532203A
Other languages
English (en)
Inventor
Hakon Hakonarson
Mark E. Gurney
Eva Halapi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Decode Genetics ehf
Original Assignee
Decode Genetics Ehf.
Hakon Hakonarson
Mark E. Gurney
Eva Halapi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics Ehf., Hakon Hakonarson, Mark E. Gurney, Eva Halapi filed Critical Decode Genetics Ehf.
Publication of CA2532203A1 publication Critical patent/CA2532203A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
CA002532203A 2003-07-14 2004-07-14 Methodes de diagnostic et de traitement de l'asthme et d'autres maladies respiratoires reposant sur une association d'haplotypes Abandoned CA2532203A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48707203P 2003-07-14 2003-07-14
US60/487,072 2003-07-14
US55961104P 2004-04-05 2004-04-05
US60/559,611 2004-04-05
PCT/US2004/022446 WO2005007144A2 (fr) 2003-07-14 2004-07-14 Methodes de diagnostic et de traitement de l'asthme et d'autres maladies respiratoires reposant sur une association d'haplotypes

Publications (1)

Publication Number Publication Date
CA2532203A1 true CA2532203A1 (fr) 2005-01-27

Family

ID=34083403

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002532203A Abandoned CA2532203A1 (fr) 2003-07-14 2004-07-14 Methodes de diagnostic et de traitement de l'asthme et d'autres maladies respiratoires reposant sur une association d'haplotypes

Country Status (5)

Country Link
EP (1) EP1646372A2 (fr)
AU (1) AU2004257748B2 (fr)
CA (1) CA2532203A1 (fr)
MX (1) MXPA06000514A (fr)
WO (1) WO2005007144A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
PT2161038E (pt) * 2006-01-26 2014-03-10 Isis Pharmaceuticals Inc Composições e suas utilizações dirigidas à huntingtina
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
JP5133416B2 (ja) 2007-09-14 2013-01-30 オルソー−マクニール−ジャンセン ファーマシューティカルズ， インコーポレイテッド． １’，３’−二置換−４−フェニル−３，４，５，６−テトラヒドロ−２ｈ，１’ｈ−［１，４’］ビピリジニル−２’−オン
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
WO2009062676A2 (fr) 2007-11-14 2009-05-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Dérivés imidazo[1,2-a]pyridine et leur utilisation comme modulateurs allostériques positifs des récepteurs mglur2
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
EP2346505B1 (fr) 2008-10-16 2014-04-23 Janssen Pharmaceuticals, Inc. DÉRIVÉS D'INDOLE ET DE BENZOMORPHOLINE EN TANT QUE MODULATEURS DE RÉCEPTEURS MÉTABOTROPIQUEs DU GLUTAMATE
WO2010060589A1 (fr) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Dérivés d'indole et de benzoxazine comme modulateurs des récepteurs métabotropiques au glutamate
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2430031B1 (fr) 2009-05-12 2013-04-17 Janssen Pharmaceuticals, Inc. Dérivés de 1,2,4-triazolo [4,3-A]pyridine et leur utilisation en tant que modulateurs allostériques positifs de récepteurs mGluR2
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
AU2011328195B2 (en) 2010-11-08 2015-04-02 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2012062750A1 (fr) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. Dérivés de 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
IL279202B2 (en) 2014-01-21 2023-09-01 Janssen Pharmaceutica Nv Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
PL3431106T3 (pl) 2014-01-21 2021-06-28 Janssen Pharmaceutica Nv Kombinacje zawierające pozytywne modulatory allosteryczne metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2184106T3 (es) * 1996-06-25 2003-04-01 Cephalon Inc Utilizacion del derivado de k-252a en el tratamiento de trastornos del sistema nervioso periferico o central, y de la hiperproduccion de citoquinas.
IL144515A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc A pcr-based multiplex assay for determining haplotype
IL154311A0 (en) * 2000-08-11 2003-09-17 Cephalon Inc Modulating multiple lineage kinase proteins
WO2003064428A1 (fr) * 2002-01-29 2003-08-07 H. Lundbeck A/S Furano- et thienopyrimidines en tant qu'inhibiteurs de la neurokinase

Also Published As

Publication number Publication date
AU2004257748B2 (en) 2008-10-30
MXPA06000514A (es) 2006-06-20
AU2004257748A1 (en) 2005-01-27
EP1646372A2 (fr) 2006-04-19
WO2005007144A3 (fr) 2005-06-16
WO2005007144A2 (fr) 2005-01-27

Similar Documents

Publication Publication Date Title
US20060014165A1 (en) Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
AU2004257748B2 (en) Method of diagnosis and treatment for asthma based on haplotype association
CA2612475C (fr) Variants dans le gene tcf7l2 utilises en tant que marqueurs diagnostiques pour le risque de diabete de type ii
US20050287551A1 (en) Susceptibility gene for human stroke; methods of treatment
EP1871908B1 (fr) Gene de susceptibilite de l'infarctus du myocarde et du syndrome coronarien aigu
US20050164220A1 (en) Susceptibility gene for human stroke: method of treatment
US20050272051A1 (en) Methods of preventing or treating recurrence of myocardial infarction
JP2006508180A (ja) 心筋梗塞に対する感受性遺伝子；治療の方法
AU2003201728B2 (en) Gene for peripheral arterial occlusive disease
WO2003076658A2 (fr) Gene de predisposition a la maladie de parkinson idiopathique a apparition tardive
US20060141462A1 (en) Human type II diabetes gene-slit-3 located on chromosome 5q35
AU2003201728A1 (en) Gene for peripheral arterial occlusive disease
US20040014099A1 (en) Susceptibility gene for human stroke; methods of treatment
US20050214780A1 (en) Human type II diabetes gene - Kv channel-interacting protein (KChIP1) located on chromosome 5
CA2499320A1 (fr) Gene de predisposition pour l'attaque chez l'homme, et procedes de traitement
WO2005123964A2 (fr) Gene de susceptibilite pour les accidents vasculaires cerebraux chez l'humain et procedes de traitement

Legal Events

Date Code Title Description
FZDE Dead